Loading...
Loading...
INTS| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 100.5K |
| Gross Profit | -100.5K |
| Operating Expense | 1,253.8K |
| Operating I/L | -1,254.1K |
| Other Income/Expense | -82.1K |
| Interest Income | 0.3K |
| Pretax | -1,336.1K |
| Income Tax Expense | 0.4K |
| Net Income/Loss | -1,336.5K |
Intensity Therapeutics, Inc. is a clinical-stage biotechnology company specializing in the development and commercialization of cancer drugs for solid tumors. Its lead product candidate, INT230-6, is in Phase 2 clinical trials for refractory solid tumors and various cancer types including pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. The company has collaboration agreements with Merck, Bristol-Myers Squibb, Ottawa Hospital Research Institute, and the Ontario Institute of Cancer Research to evaluate the combination of INT230-6 with other drugs in treating advanced cancers.
